In January sixty-three medical products underwent label revisions, with changes to the prescribing information to include any of the following areas: boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert, and medication guide.
The following medications have been affected:
- Accupril
- Accuretic
- Altace
- Avalide
- Avapro
- Azor
- Benicar HCT
- Diovan
- Diovan HCT
- Exforge
- Exforge HCT
- Lotensin
- Lotensin HCT
- Lotrel
- Mavik
- Micardis
- Micardis HCT
- Tarka
- Teveten
- Teveten HCT
- Tribenzor
- Univasc
- Uniretic
- Ceftriaxone for Injection and Dextrose Injection in Duplex Container
- Evoclin
- Mavik
- Micardis
- Micardis HCT
- Micardis HCT
- Twynsta
- Xenical
- Chantix
- Erbitux
- Fanapt
- Fazaclo
- Gralise
- Morphine Sulfate Oral Solution
- Morphine Sulfate Tablets
- Nexium
- Nexium
- Performist
- Pradaxa
- Vimovo
- Vytorin
The attorneys of Jones Ward PLC represent hundreds of persons all across the country who have been injured by defective products, prescription drugs and medical devices. If you or someone you know has been injured by one of the above prescription drugs or any other type of product, contact attorney Terrance Massey. You can reach him by phone at (502) 882-6000 or by email at tj@jonesward.com.
